Site Map

Waldenstrom macroglobulinemia

Waldenström macroglobulinemia; Macroglobulinemia - primary; Lymphoplasmacytic lymphoma; Monoclonal macroglobulinemia; Waldenström macroglobulinemia

Waldenström macroglobulinemia (WM) is a cancer of the B lymphocytes (a type of white blood cell). WM is associated with the overproduction of proteins called IgM antibodies.

Images

Waldenstroms
Antibodies

Causes

WM is a result of a condition called lymphoplasmacytic lymphoma. This is a cancer of the white blood cells, in which the B immune cells start dividing rapidly. The exact cause of too much production of the IgM antibody is unknown. Hepatitis C may increase the risk of WM. Gene mutations are often found in the malignant B cells.

Production of excess IgM antibodies can cause several types of problems:

WM is very rare. Most people with this condition are over 65 years of age.

Symptoms

Symptoms of WM may include any of the following:

Exams and Tests

A physical examination may reveal a swollen spleen, liver, and lymph nodes. An eye exam may show enlarged veins in the retina or retinal bleeding (hemorrhages).

A CBC may show a low number of red blood cells or platelets. Blood chemistry may show evidence of kidney disease.

A test called serum protein electrophoresis shows an increased level of the IgM antibody. Levels are often higher than 300 milligrams per deciliter (mg/dL), or 3000 mg/L. An immunofixation test will be done to show that the IgM antibody is derived from a single cell type (clonal).

A serum viscosity test can tell if the blood has become thick. Symptoms usually occur when the blood is four times thicker than normal.

A bone marrow biopsy will show increased numbers of abnormal cells that look like both lymphocytes and plasma cells.

Additional tests that may be done include:

Treatment

Some people with WM who have increased IgM antibodies do not have symptoms. This condition is known as smoldering WM. No treatment is needed other than careful follow-up.

In people with symptoms, treatment aims at decreasing the symptoms and the risk of developing organ damage. There is no current standard treatment. Your health care provider may suggest that you participate in a clinical trial.

Plasmapheresis removes IgM antibodies from the blood. It also controls the symptoms caused by blood thickening.

Medicines may include corticosteroids, a combination of chemotherapy medicines and the monoclonal antibody to B cells, rituximab.

Autologous stem cell transplant may be recommended for some people with otherwise good health.

People who have a low number of red or white blood cells or platelets may need transfusions or antibiotics.

Outlook (Prognosis)

The average survival is about 5 years. Some people live more than 10 years.

In some people, the disorder may produce few symptoms and progress slowly.

Possible Complications

Complications of WM may include:

When to Contact a Medical Professional

Contact your provider if symptoms of WM develop.

Related Information

Polycythemia - newborn
Vision problems
Decreased alertness
Heart failure

References

Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017;3(9):1257-1265. PMID: 28056114 pubmed.ncbi.nlm.nih.gov/28056114/.

Rajkumar SV. Plasma cell disorders. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 178.

Treon SP, Castillo JJ, Hunter ZR, Merlini G. Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 87.

BACK TO TOP

Review Date: 4/19/2022  

Reviewed By: Diane M. Horowitz, MD, Rheumatology and Internal Medicine, Northwell Health, Great Neck, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo
Health Content Provider
06/01/2025

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complied with the HONcode standard for trustworthy health information from 1995 to 2022, after which HON (Health On the Net, a not-for-profit organization that promoted transparent and reliable health information online) was discontinued.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.